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Abstract 
 
Cellular DNA is under constant attack by a wide variety of agents, both 
endogenous and exogenous. To counteract DNA damage, human cells have a 
large collection of DNA repair factors. Among them, DNA polymerase lambda 
(Polλ) stands out for its versatility, as it participates in different DNA repair and 
damage tolerance pathways in which gap-filling DNA synthesis is required. In 
this work we show that human Polλ is conjugated with Small Ubiquitin-like 
MOdifier (SUMO) proteins both in vitro and in vivo, with Lys27 being the main 
target of this covalent modification. Polλ SUMOylation takes place in the nuclear 
pore complex and is mediated by the E3 ligase RanBP2. This post-translational 
modification promotes Polλ entry into the nucleus, which is required for its 
recruitment to DNA lesions and stimulated by DNA damage induction. Our work 
represents an advance in the knowledge of molecular pathways that regulate 
cellular localization of human Polλ, which are essential to be able to perform its 
functions during repair of nuclear DNA, and that might constitute an important 
point for the modulation of its activity in human cells. 
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INTRODUCTION 
Cellular metabolism daily produces thousands of molecules that are able to 
generate a variety of DNA lesions, ranging from simple nucleotide changes to 
DNA breaks [1]. To deal with all DNA lesions, human cells have evolved a 
variety of repair mechanisms that ensure the maintenance of genome integrity 
at every cell cycle, avoiding the pathological consequences that might result 
from a defective response to DNA damage [2,3]. Short-patch DNA synthesis to 
fill small gaps is required in virtually all these DNA repair pathways. This gap-
filling DNA synthesis is a singular reaction mainly performed by X-family 
specialized DNA polymerases [4], which develop their abilities in diverse 
escenarios, such as base excision repair [5], the repair of or tolerance to 
oxidative damage [6,7] and the repair of DNA double strand breaks (DSBs) [8-
11]. Among the four PolX members identified in human cells to date, namely 
Polß, terminal deoxynucleotidyl transferase (TdT), Polµ, and Polλ, the latter 
shows the broadest range of action in DNA repair and tolerance to DNA 
damage [12]. Functional versatility of Polλ suggests interaction with multiple co-
factors in the different pathways in which its gap-filling activity is required, 
probably implying a complex regulation. In agreement to this, previous studies 
have revealed cell cycle and DNA damage-dependent phosphorylation-
mediated regulation of human Polλ [13-15]. 
 
 Post-translational modification (PTM) of proteins plays an essential role 
in the proper functioning and viability of eukaryotic cells. Amongst the different 
PTMs identified to date, conjugation of Small Ubiquitin-like MOdifier (SUMO) 
proteins seems crucial in human cells, as it plays relevant roles in key cellular 
processes, such as DNA replication, transcription and general maintenance of 
genomic stability [16-19]. SUMOylation is a highly dynamic and transient 
process that promotes covalent attachment of SUMO moieties to specific lysine 
residues on target proteins. This reaction is reversible thanks to the existence of 
a variety of SUMO-specific proteases (SENPs) that efficiently remove SUMO 
proteins from targeted substrates [16,17]. Importantly, SUMOylation can protect 
proteins from ubiquitin-mediated proteasomal degradation, probably competing 
with ubiquitination machinery for the same target lysine residues [17,20]. In 
human cells, there are at least three main SUMO paralogs. SUMO1 shares 
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approximately 45% sequence identity with SUMO2 and 3, and these two are 
96% identical to each other. These SUMO proteins are approximately 12 kDa in 
size and structurally very similar to ubiquitin [20]. SUMO substrates are mainly 
proteins with nuclear functions, that can be modified either with a single SUMO 
moiety (mono-SUMO), multiple SUMO units at different sites (multi-SUMO) or 
with SUMO chains formed at one specific target site (poly-SUMO). In this 
regard, SUMO paralogs also differ in their ability to form polymeric chains, as 
SUMO2 and 3 possess internal Lys residues that can serve as SUMO acceptor 
sites in an auto-modification process that SUMO1 does not have [21]. Likewise, 
there are substantial differences in the dynamics of SUMO paralogs, because 
while SUMO1 is mainly found within the nucleoli, the nuclear envelope and 
cytoplasmic foci, SUMO2/3 are distributed throughout the nucleoplasm [22]. 
Moreover, whereas SUMO1 mainly exists in the protein-conjugated form, 
vertebrate cells have a large pool of free SUMO2/3 [22, 23], which is 
conjugated to high molecular mass proteins when cells are subjected to protein-
damaging stimuli [23,24]. Covalent attachment of SUMO moiety to target 
proteins occurs in a three-step sequential process, frequently at specific 
consensus sequences [16,17]. The SUMO conjugation process is initiated by 
covalent binding of SUMO protein to the SUMO-activating enzyme SAE1 (E1) 
through a thioester bond. This is followed by SUMO transference to a second 
factor, Ubc9 (E2), to form an E2-SUMO1 complex. Although Ubc9 can directly 
transfer the SUMO to acceptor Lys residues on target protein, this reaction is 
facilitated in vivo by a group of E3 protein ligases, whose mediation is specially 
relevant for substrate selection in proteins lacking SUMO acceptor consensus 
sequences [20]. The different SUMO E3 ligases identified so far have distinct 
subcellular localization, reflecting different biological functions of SUMO 
modification [25]. Accordingly, whereas RanBP2 is associated with the nuclear 
pore complex, and has been related to nucleo-cytoplasmic trafficking of specific 
proteins [26], PIAS, Pc2/CBX4 and others are essentially found in the nucleus, 
where they play roles in a wide variety of biological processes, from 
transcription regulation and chromatin remodeling to the maintenance of cellular 
homeostasis and genome integrity [16,17,20]. 
 
Here we report that DNA polymerase lambda (Polλ) is one of the protein targets 
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for SUMOylation in human cells and uncover the biological role of this post-
translational modification. We identify human Polλ lysine 27 (K27) as the main 
acceptor site for the covalent attachment of SUMO proteins both in vitro and in 
vivo, and demonstrate that the lack of SUMOylation results in deficient import of 
Polλ into the nucleus. We also identify the role of nuclear pore complex-
associated RanBP2 protein as the main E3 ligase required for Polλ 
SUMOylation in the cytoplasm, allowing its entry into the nucleus and its 
function during DNA repair. Overall, our work provides insights into the 
regulation of Polλ during the DNA damage response and its potential use to 
control the quantity and/or quality of Polλ-mediated DNA repair events.
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
RESULTS and DISCUSSION 
Human Polλ is SUMOylated in vitro and in vivo  
Analysis of human Polλ amino acid sequence by specialized software 
(SUMOplot, by Abgent; http://www.abgent.com/sumoplot) suggested that Polλ 
can be modified by SUMOylation. To confirm this prediction, we performed in 
vitro SUMOylation assays using purified proteins (Figure 1A and 
Supplemental Figure 1A and 1B). In these assays we observed the 
appearance of low electrophoretic mobility species exclusively in the presence 
of ATP, an essential requirement for SUMO conjugation catalysis. A main 
modified protein showed an apparent increase in molecular weight of about 15-
20 kDa with respect to unmodified protein when either SUMO1 or SUMO2 were 
included in the assays. This increase was in agreement with mono-
SUMOylation of human Polλ (Figure 1A). Moreover, other less represented 
species with slightly lower electrophoretic mobility were also observed with both 
SUMO paralogs, suggesting that different lysine residues could be additionally 
targeted with SUMO, although with less efficiency (Figure 1A). We next 
analyzed whether Polλ SUMOylation also occurred in vivo by performing Ni-
NTA pulldowns under denaturing conditions from human 293T cells co-
expressing Flag-Polλ, His-SUMO1 and Ubc9, the only known E2 conjugation 
enzyme in mammalian cells. In these experimental conditions, SUMOylation of 
human Polλ was very efficient, and the size of the different low electrophoretic 
mobility species observed suggested the formation of poly-SUMO chains 
(Supplemental Figure 1C). Of note, although a fraction of unmodified Polλ was 
pulled down from all samples, SUMO-Polλ species were stricly dependent on 
His-SUMO1 over-expression (Supplemental Figure 1C). Notably, Polλ 
SUMOylation was detected at endogenous levels of Ubc9, and was strongly 
reduced in the presence of a dominant negative Ubc9 mutant (Ubc9-C93S) that 
cannot catalyze SUMO conjugation to target proteins [27] (Supplemental 
Figure 1C). SUMOylation of Polλ in vivo was also confirmed by using 
engineered human U2OS cell lines stably expressing His-tagged SUMO 
paralogs [28,29]. These cells were transiently transfected with the plasmid 
encoding for Flag-Polλ, and SUMO conjugates were pulled down from cell 
extracts as described above. In these experimental conditions, efficient 
SUMOylation of Polλ was also observed both with SUMO1 and SUMO2 
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paralogs, being the modification undetectable in control U2OS cells with 
untagged SUMO proteins (Figure 1B). Noteworthy, poly-SUMO chain formation 
in these experimental conditions was prevented by the molecular features of 
His-tagged SUMO paralogs expressed in these engineered cells [28,29].  
 
Identification of Polλ SUMOylation sites 
Our initial analysis in silico predicted lysine 27 (K27) as the amino acid residue 
with the highest probability to be targeted by SUMO moiety in human Polλ 
(Supplemental Figure 2A and 2B). K27 is embedded in a highly conserved 
non-consensus SUMOylation motif located at the most N-terminal region of the 
protein (AKIP, with the underlined residue being the SUMO target; 
Supplemental Figure 2A). This region is characterized by a great flexibility, 
that would be in agreement with previously reported SUMO preferential 
targeting to highly disordered regions [29]. We confirmed initial prediction by 
performing in vitro SUMOylation assays using peptide arrays that covered the 
most N-terminal region of human Polλ, including both K27 and all its proximal 
lysine residues (residues 8, 12, 15 and 23; Figure 1C and 1D). These assays 
showed the strongest SUMO targeting in peptides containing K27 (Figure 1D), 
according to proteome-wide studies that had also identified this residue as the 
main target for Polλ SUMOyl tion (Supplemental Figure 2C) [29]. We 
therefore generated the most conservative mutation of SUMO acceptor lysine 
(K27R mutation) and analyzed the effect on SUMOylation in vivo, as described 
above. In these assays, whereas a reduction of SUMO1 conjugation could not 
be detected in K27R mutant compared to wild-type Polλ, an evident decrease 
was observed in the case of SUMO2 conjugation (Figure 1E and 1F). This 
effect could be explained to some extent by the lower efficiency of SUMO2 
conjugation compared to SUMO1, already observed in vitro (Figure 1B). 
Likewise, these assays suggested the existence of alternative SUMOylation 
target sites in Polλ, also in agreement with results obtained in vitro (Figure 1A) 
and with proteomic studies that identified K8 and K23 residues as alternative 
(secondary) lysines for SUMOylation in the N-terminal region (Supplemental 
Figure 2C) [29]. To prevent SUMOylation of these alternative sites, we 
generated a mutant in which all seven N-terminal lysine residues, including K8, 
K12, K15, K23, K27 and two additional and more distant ones (K63 and K111) 
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were equally substituted by arginines (mutant 7KR; Figure 1C), and analyzed 
the effect of these mutations in SUMOylation of Polλ. Of note, all these 
conservative mutations are localized in the N-terminal end of Polλ, very far from 
the catalytic domain and in a protein domain that has been shown to be 
needless for polymerization activity. This analysis showed a dramatic decrease 
of SUMO conjugation efficiency in 7KR mutant compared with wild-type Polλ, 
both with SUMO1 and SUMO2 (Figure 1E and 1F). We obtained fully 
confirmation of Polλ K27 residue SUMO-specific targeting in vivo through 
generation of an additional mutant protein in which all N-terminal lysine residues 
except such K27 were mutated to arginine (mutant 6KR). Notably, this 6KR 
mutant fully recovered SUMOylation profile observed in vivo in wild-type Polλ, 
both with SUMO1 and SUMO2 (Figure 1E and 1F), indicating that K27 is a 
target for SUMOylation in vivo. These results do not rule out the possibility that 
other proximal lysine residues (i.e. K8 or K23) can play a similar role if they are 
available for SUMOylation. In agreement, SUMOylation of these two lysine 
residues have also been detected in proteomic-wide analysis, although with a 
lower frequency than K27 residue (Supplemental Figure 2C) [29]. It is worth 
noting that because SUMOylation targets lysine residues of protein substrates, 
it can potentially compete with other lysine-directed PTMs like acetylation or 
ubiquitylation [17]. Indeed, Polλ K27 has been identified as a target for 
ubiquitination, which controls Polλ levels during cell cycle [30]. In light of our 
results, it is tempting to speculate that K27 SUMOylation could antagonize the 
effects of ubiquitin, a competitive relationship that has been reported in many 
other proteins, including some DNA damage response factors [2,17]. 
 
SUMOylation regulates subcellular localization of human Polλ 
One of the first roles assigned to SUMOylation in vivo is to regulate subcellular 
localization of some target proteins, such as RanGAP protein, the first identified 
SUMO substrate [31]. Therefore, we analyzed by immunofluorescence the 
subcellular localization of Flag-tagged Polλ versions, including wild-type, 
mutants analyzed in previous in vivo assays (K27R, 7KR and 6KR) and two 
additional mutants affecting the nearest lysine amino acid residue K23 (K23R 
and K23/27R) (Figure 2A). As expected from a DNA repair polymerase, the 
distribution of wild-type Polλ in human U2OS cells was predominantly nuclear 
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(more than 92% cells). In contrast, Polλ K27R single mutant showed a markedly 
different subcellular distribution, with a fraction of the protein remaining outside 
the nucleus (more than 25%; p<0.01 in Anova test). This effect was specific of 
K27 amino acid residue, as it was not observed when mutation affected K23 
residue (Figure 2A). The abnormal distribution seen in K27R mutant was 
strongly exacerbated in Polλ 7KR, the mutant that was barely SUMOylated in 
vivo (Figure 1E and 1F), which was almost completely excluded from the 
nucleus (Figure 2A). Notably, this cytoplasmic distribution was abolished when 
the K27 residue became available again for SUMOylation, in the 6KR mutant, 
completely recovering the nuclear localization observed in the wild-type Polλ 
(Figure 2A). These results suggest that SUMOylation at K27 residue controls 
Polλ entry into the nucleus in vivo. Alternatively, SUMO modification might be 
required to retain Polλ within the nucleus. To evaluate this possibility, we 
analyzed the effect of leptomycin B (LMB) in the subcellular localization of the 
Polλ 7KR mutant protein. LMB is an inhibitor of the nuclear-cytoplasmic 
shuttling of proteins that contain specific nuclear export signals [32], and human 
Polλ has a predicted nuclear export signal at the BRCT domain. The presence 
of LMB did not have any effect on the distribution of Polλ K7R protein 
(Supplemental Figure 3), indicating that SUMOylation is not required to retain 
Polλ inside the nucleus and pointing towards a role in the translocation of Polλ 
from the cytoplasm into the ucleus. To directly confirm this hypothesis, we 
generated Polλ SUMOylation mimetic constructs and analyzed their subcellular 
localization by means of immunofluorescence. These constitutive SUMO-Polλ 
versions were obtained by translational fusion of mature SUMO1 or SUMO2 to 
the N-terminus of Polλ K7R mutant protein (Supplemental Figure 4A). We also 
replaced SUMO specific C-terminal double glycine residues by alanine residues 
in fusion proteins (S1-fusAA and S2-fusAA, respectively) to avoid SUMO 
removal due to the strong activity of SUMO-specific proteases (SENPs) in vivo 
[16] (Supplemental Figure 4A). Genetic fusion of either SUMO1-AA or 
SUMO2-AA to Polλ 7KR mutant did not restore nuclear localization of Polλ 
(Supplemental Figure 4B), suggesting that the presence of SUMO moiety in 
the N-terminus of Polλ, although necessary, is not enough to facilitate its entry 
into the nucleus. Nevertheless, given that both dynamism and reversibility are 
essential for cellular roles of SUMOylation, it is very likely that these fusion 
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proteins might be incompatible with nucleo-cytoplasmic shuttling functions. A 
defect in the proper and functional folding of fusion proteins cannot be ruled out 
either. Regardless, our study uncovers the pivotal role of SUMOylation in the 
control of cellular distribution of Polλ, and identify the molecular basis of 
previous observations that Polλ catalytic core, a protein version lacking the 
amino terminal region including BRTC and Ser-Pro rich domains, is not able to 
enter into the nucleus [33,34]. 
 
Lack of SUMOylation results in decreased Polλ recruitment to etoposide-
induced DNA damage 
Given its relevance in the nuclear localization of Polλ, we wanted to determine 
the consequences of interfering with SUMOylation on its recruitment to DNA 
lesions. To specifically measure Polλ recruitment to DNA damage, we 
developed an experimental approach based on proximity ligation assays (PLA) 
that uses specific antibodies for human Polλ and phosphorylated histone H2AX 
(γH2AX), a well known marker of DNA damage in mammalian cells [35,36]. We 
validated the use of this molecular tool to measure the recruitment of Polλ to 
DNA damage sites in vivo by analyzing the formation of PLA foci of 
endogenous γH2AX and Polλ in human U2OS cells treated with etoposide. In 
these experimental conditions, we observed an increase in the number of PLA 
foci that was directly proportio al to the dose of etoposide used (Supplemental 
Figure 5). Once validated the assay, we performed additional experiments in 
U2OS cells that were pre-treated with specific siRNAs to remove endogenous 
Polλ, and that concomitantly overexpressed similar levels of siRNA-resistant 
versions of either wild-type Polλ or Polλ 7KR mutant (Figure 2B). In these 
experimental conditions, U2OS cells expressing wild-type Polλ showed an 
increase in Polλ-γH2AX PLA foci in response to etoposide-induced DNA 
damage (untreated WT median 8.0 vs. etoposide-treated WT median 47.5; 6-
fold increase, p<0.001, Anova test) (Figure 2C). Notably, U2OS cells 
expressing Polλ 7KR mutant showed a decrease in Polλ-γH2AX PLA foci after 
etoposide-induced DNA damage with respect to wild-type Polλ (WT median 
47.5 vs. 7KR median 18; 3-fold decrease, p<0.001, Anova test) (Figure 2C and 
2D). These results indicate that recruitment of Polλ to etoposide-induced DNA 
damage sites is reduced when its SUMOylation-mediated entry into the nucleus 
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is impeded. Noteworthy, some Polλ-γH2AX PLA signal is still observed in cells 
expressing Polλ 7KR (etoposide 7KR median 18 vs. untreated 7KR median 5) 
(Figure 2C), although etoposide treatment did not largely changed the 
distribution of this mutant protein (Supplemental Figure 6). This is indicative 
that some Polλ has to be into the nucleus, that can probably be due to 
incomplete silencing of POLL expression 
However, alternative routes or complementary mechanisms for Polλ nuclear 
entry and recruitment to DNA damage sites, independently of the SUMO-
mediated pathway, cannot be excluded. Accordingly, novel interactions 
between Polλ NLS derived peptides and cellular importins have been recently 
described [37]. Future studies, both structural and functional, will clarify these 
alternative pathways and putative synergies with the findings uncovered in our 
study. 
 
RanBP2 E3 ligase mediates Polλ SUMOylation and nuclear localization 
SUMOylation of natural substrates in vivo is facilitated by a variety of E3 protein 
ligases, specially in proteins, as Polλ, lacking consensus SUMO acceptor motifs 
[16,25]. To date, the only non-nuclear E3 ligase identified is nuclear pore 
complex-associated RanBP2 protein, that can form a stable complex with both 
SUMO1 and Ubc9 throughout the cell cycle and promote the last step in the 
SUMOylation process [38-40]. Considering this, and the nucleo-cytoplasmic 
shuttling defect seen in our Polλ mutants (Figure 2A), we reasoned that 
RanBP2 could be the E3 ligase involved in Polλ SUMOylation. Supporting this 
possibility, proximity ligation assays (PLA) detected physical proximity between 
RanBP2 and Polλ predominantly in the outer side of nuclear envelope (Figure 
3A and Supplemental Figure 7). Moreover, we detected direct interaction of 
these two proteins by co-immunoprecipitation in the absence of any external 
stimulus (Figure 3B), suggesting that Polλ might be targeted for RanBP2-
mediated SUMOylation constitutively. To verify a functional interaction between 
RanBP2 E3 ligase and Polλ, we performed His-SUMO pulldown assays as 
those described above in U2OS cells that were previously treated with RanBP2 
specific siRNAs. In these experimental conditions, we observed that the 
reduction in RanBP2 expression led to a strong concomitant decrease in 
conjugation of SUMO to Polλ (Figure 3C and 3D). This effect was not seen in 
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cells treated with control non-targeting siRNAs, so that confirmed RanBP2 as 
the main E3 ligase involved in Polλ SUMOylation. In the same way, 
immunofluorescence assays performed in Flag-Polλ expressing U2OS cells that 
had been silenced for RanBP2 expression also showed a strong decrease of 
Flag-Polλ nuclear localization when compared to cells treated with control non-
targeting siRNAs (Figure 3E; more that 40% reduction in nuclear localization; 
p<0.001 in an unpaired t-test). These results were in fully agreement with those 
obtained with non-SUMOylatable Polλ mutants in our in vivo SUMOylation 
assays (Figure 2A). Altogether, our results indicate that RanBP2 is the main E3 
ligase participating in SUMO-mediated modification of human Polλ to promote 
its nuclear import. Of note, nuclear import of artificial cargos can still occur in 
vivo in RanBP2-depleted cells, although rates are substantially reduced [26]. 
This could explain residual nuclear Polλ observed in our analyses with K27R 
single mutant (Figure 2A), and, again, suggest the existence of SUMO-
independent pathways, still to be deciphered, through which Polλ could enter 
into the nucleus. 
 
Polλ SUMOylation is enhanced after MMS-mediated DNA damage 
induction 
Once demonstrated the involvement of RanBP2-dependent SUMOylation at the 
nuclear pore complex in the translocation of Polλ into the nucleoplasm, we 
wanted to determine if this molecular mechanism was affected by DNA 
damage. By using engineered human U2OS cell lines stably expressing His-
tagged SUMO paralogs described above, we were able to efficiently detect 
SUMOylation of endogenous Polλ in Ni-NTA pull down assays (Figure 4A). 
This allowed us to evaluate the effect of DNA damage induction on Polλ 
SUMOylation in more physiological conditions. Such analysis revealed an 
increase of Polλ SUMOylation when cells were subjected to DNA damage 
induction, being the increase specially evident in response to the DNA 
alkylating agent methyl methanesulfonate (MMS) (Figure 4B and 4C). MMS-
induced DNA lesions are mainly repaired by base excision repair (BER), a 
repair pathway in which DNA polymerase ß is the main gap-filling DNA 
polymerase [41,42]. Although Polλ participation in this repair route was initially 
suggested as a back-up mechanism in mouse cells [43], it has also been shown 
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that cells deficient in both Polλ and Polß are hypersensitive to MMS [5], 
suggesting that both PolX enzymes synergistically participate in the repair of a 
common set of DNA lesions. Interestingly, it has been recently reported that 
human Polλ can also perfectly complement the absence of Polß in POLB-
deficient cell extracts, leading authors to suggest that Polλ might be 
sequestered in vivo in a complex with other proteins or post-translationally 
modified in a way that limits its ability to participate effectively in BER in normal 
conditions [44]. Overall, our results would be in agreement with a model in 
which, if Polß is overcome by the amount of damage generated by MMS, a 
greater requirement of nuclear Polλ would be needed, that might be achieved 
through the SUMO-mediated translocation of Polλ into the nucleus. It is worth 
noting that main SUMOylation site in Polλ (K27 residue) is, in turn, target site for 
ubiquitination, which is a signal for its subsequently degradation via proteasome 
[30].  Therefore, it cannot be ruled out that SUMOylation at K27 makes Polλ 
more stable and, therefore, more active in the repair of MMS-induced damage. 
Future studies will be necessary to validate this model and elucidate the precise 
role of Polλ SUMOylation in BER regulation. On the other hand, it is equally 
noteworthy that MMS produces a wide variety of DNA lesions, some of which 
prevent the progression of replication forks [45]. Therefore, one possibility 
would be that the increase in Polλ SUMOylation in response to MMS is related 
to replication forks problems. In agreement with this, replicative stress induced 
with hydroxyurea (HU) also caused a concomitant increase in SUMOylation of 
Polλ (Figure 4C and Supplemental Figure 8). In spite of this, we did not detect 
significant differences in Polλ SUMOylation at different stages of a cell cycle in 
human U2OS cells (Figure 4D). Overall, our data suggest that SUMOylation is 
a relevant signal for human Polλ to entry the nucleus in situations where its gap-
filling activity can be specially required, e.g., during MMS-triggered BER or upon 
replicative stress. 
 
Concluding Remarks 
Detailed knowledge of the post-translational regulation of DNA repair proteins is 
essential to understand how cells deploy the complicated and tangled network 
of processes that constitute the DNA damage response. Finely coordinated 
functioning of this complex network will determine cell viability and prevent the 
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development of age-related diseases and cancer. In particular, it is of great 
interest to decipher the molecular mechanisms that allow DNA repair factors to 
enter the nucleus and accomplish their functions, which can have negative 
consequences for the cell, for example contributing to tumorigenesis as a 
consequence of inefficient DNA repair [45]. In this work we have identified 
SUMOylation as a novel post-translational modification of human DNA repair 
polymerase lambda (Polλ) with a relevant influence in its potential functionality 
in vivo. We have uncovered that SUMO modification fundamentally occurs at N-
terminal K27 amino acid residue and requires E3 activity ligase from RanBP2, a 
nucleoporin present in the outer side of the nuclear envelope. Likewise, we 
have discovered that nuclear localization of human Polλ is SUMO-dependent, 
so that such modification is required for Polλ to be recruited to DNA lesions to 
perform its function. It is worth noting that transport pathways may offer 
attractive therapeutic targets, as they represent a very selective way of 
cancelling a biological activity without affecting others. Consequently, the nature 
of the molecular pathway described here suggests that preventing Polλ 
SUMOylation by using small molecule inhibitors of this specific modification (for 
example, blocking SUMO-acceptor sites) could be a suitable point to abolish its 
polymerase activity in the nucleus, which could be interesting in order to explore 
the effect of selective Polλ inhibition on tumor cell growth. High levels of 
replicative stress and excess of oxidative lesions (i.e. ROS) are a hallmark of 
tumor cells that will demand a great functioning of BER and DNA damage 
tolerance pathways. Disrupting the cellular mechanisms that cope with this 
aberrant situation, for example by inhibiting the ATR or Chk1 kinases, 
constitutes a very promising strategy for cancer treatment [47,48]. Interestingly, 
the suppression of Polλ activity induces synthetic lethality when combined with 
Chk1 inhibitors [49], what turns Polλ and its nucleo-cytoplasmic shuttling as 
additional potential chemotherapeutic target to be analyzed in more detail. 
Importantly, targeting the N-terminal region of Polλ would solve undesired 
effects of many of Polλ inhibitors identified so far, that can also affect other 
polymerases, in particular those from PolX family, due to high similarity in their 
catalytic center [50,51]. Although further structural studies should be needed to 
gain molecular insights of Polλ N-terminal region, some pioneering work 
performed with the murine ortholog already shed some light in this regard [33]. 
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Finally, another attractive scenario to be explored regarding Polλ SUMOylation 
inhibition would be related with CRISPR-Cas based gene editing tools. These 
systems strongly rely on the processing of directed DSBs by the cellular NHEJ 
repair machinery. The possibility of controlling CRISPR-based gene editing 
accuracy by pharmacological modulation of the repair process is being 
intensively evaluated at present [52]. In this regard, the search for selective 
inhibitors against Polλ SUMOylation could also be useful in the gene editing 
toolkit, given that a large subset of breaks generated by CRISPR-Cas systems 
requires specialized DNA gap-filling activity by PolX polymerases as Polλ 
[53,54].  
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MATERIALS AND METHODS 
Cell cultures 
Human embryonic kidney 293T cells and human osteosarcoma cells (U2OS, 
U2OS HIS-SUMO1 and -SUMO2 expressing cells) [28,29] were cultured in 
DMEM medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), 2 
mM L-glutamine and antibiotics (100 units/ml penicillin, 100 μg/ml streptomycin; 
Sigma) at 37°C in a humidified atmosphere containing 5% CO2. Transient 
transfections of plasmids were performed with Lipofectamine (Life 
Technologies) according to manufacturer’s instructions. 
 
Plasmid constructs and siRNA  
Wild-type POLL cDNA was amplified by PCR and cloned in the p3xFlag-Myc-
CMV expression vector (Sigma) as previously described [15]. POLL mutants 
were generated by site directed mutagenesis using p3xFlag-[POLL]-Myc-CMV 
and overlap extension PCR methodology with oligonucleotides listed in Table 
S1. POLL K6R mutant was generated by site directed mutagenesis that 
reverted K27R mutation from p3xFlag-[POLL 7KR]-Myc-CMV plasmid, and both 
Polλ and Polλ7KR siRNA resistant clones were generated by using the 
oligonucleotides indicated in Table S1 using the p3xFlag-[POLL]-Myc-CMV and 
p3xFlag-[POLL 7KR]-Myc-CMV plasmids, respectively. All mutated cDNAs were 
verified by DNA sequencing. Constitutive SUMO-Polλ versions (both with 
SUMO1 and SUMO2) were generated by PCR amplification of either SUMO1 or 
SUMO2 cDNA by using oligonucleotide primers with flanking BglII cut sites (see 
Table S1). PCR products were digested with BglII, cloned into p3xFlag-[POLL]-
Myc-CMV expression vector and sequenced to verify proper orientation of 
fusion cDNAs. Site directed mutagenesis of the C-terminal di-glycine motif of 
SUMO proteins was performed on these plasmids by using oligonucleotides 
listed in Table S1 and overlap extension PCR methodology. Efficient silencing 
of endogenous POLL and RANBP2 genes was achieved by two consecutive 
rounds of transfection of previously validated double-stranded siRNAs (Table 
S1) [15] into human U2OS cells. Once seeded, cells were cultured for 24 hours 
and then transfected either with control (luciferase), POLL or RanBP2 specific 
siRNAs by using RNAiMAX (Life Technologies) following manufacturer’s 
instructions. Twenty-four hours later, cells were subjected to a second siRNA 
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transfection with the same siRNAs and, when indicated, either p3xFlag-[POLL]-
Myc-CMV expression vector or the corresponding control empty vector using 
Lipofectamine2000 (Life Technologies) according to manufacturer’s 
instructions. Silencing was confirmed by Western blotting analysis. The siRNA 
resistant wild-type Flag-POLL was previously described [15], and siRNA 
resistant clones of Flag-POLL 7KR were obtained by using oligonucleotides 
listed in Table S1 and Q5 Site Directed Mutagenesis kit (NEB) following 
manufacturer’s instructions. 
 
Proteins and in vitro SUMOylation assays. Mouse Ubc9, Aos1 and Uba2 
were produced in E. coli DH5α at 20°C as GST fusions and purified with 
Glutathione Sepharose 4B beads (GE, Healthcare) according to manufacturer’s 
instructions. In the case of Ubc9, GST moiety was excised by using the 
PreScission protease (GE, Healthcare). Human DNA polymerase lambda (Polλ) 
was a gift of Dr. Luis Blanco (CBM-SO, Madrid, Spain). In vitro SUMOylation 
assays with murine SUMO proteins were performed with 300 ng of purified 
Polλ. The reaction was carried out in 20 µl of standard SUMO reaction buffer 
(20 mM HEPES pH 7.5, 50 mM NaCl, 4 mM MgCl2, 0.05% Tween and 1 mM 
DTT buffer) containing 200 ng Aos1/Uba2 mix (E1), 600 ng Ubc9 (E2) and 250 
µM of the corresponding SUMO protein. Reactions were initiated with 250 µM 
ATP, incubated at 30°C for 3 h and stopped with ß-mercaptoethanol containing 
Laemmli buffer. Reactions with human SUMO proteins were performed using 
500 ng of purified human Polλ and commercially available in vitro SUMOylation 
kits (Boston Biochemicals), following manufacturer’s instructions. After in vitro 
reactions, proteins were run in SDS-PAGE 10% and immunoblotted by using 
anti-Polλ antibody (A301-640A Bethyl).  
 
In vitro SUMOylation on peptide arrays 
For in vitro SUMOylation assays on peptide-scanning arrays, N-terminal 
acetylated overlapping dodecapeptides covering the N-terminal region of 
human Polλ were generated by automated spot synthesis onto an amino-
derivatized cellulose membrane (CNB Proteomics Core Facility, Proteored, 
Spain). Peptides were immobilized by their C-termini via a polyethylene glycol 
spacer. Overlapping peptides were spotted onto membrane so that they shared 
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10 amino acids with its adjacent peptide on the array, corresponding to a 
change of two amino acids per peptide. Peptide array membrane was blocked 
overnight in 1% BSA and 3% Tween-20 before SUMO-conjugation on cellulose-
bound peptides. Briefly, enzymatic reaction was performed in a reaction mixture 
containing 5mM ATP, 50mM NaCl, 5mM MgCl2, 0.2M DTT, 1% BSA and 3% 
Tween-20, and 0.15 µM E1, 0.20 µM E2 and 0.4 µM SUMO1 proteins for 30 
min at 37ºC. Nonspecifically bound proteins were washed off by sonication for 2 
min in a bath containing 1% SDS, 0.1% ß-mercaptoethanol and 100mM 
Na2HPO4. Further nonspecific binding was blocked by incubation with 3% BSA-
1% Tween-20 in TBS for 1 hour. Subsequently, the membrane was incubated 
for 2 hours with anti-SUMO1 primary antibody diluted in blocking solution 
(1:1,000 dilution). Membranes were washed with TBS-Tween-20 (0.1%) and 
subsequently incubated with HRP-conjugated secondary antibody diluted in 
blocking solution for 1 hour. Membranes were washed extensively with TBS-T 
(0.1%) and SUMO1 signal was detected by ECL incubation following the 
manufacturer's instructions. 
 
Immunoblotting, immunoprecipitation and pulldown assays 
For western blotting analyses, 2.5x105 human 293T cells were seeded per well 
in 6-well dishes, cultured for 24 h and transfected with the corresponding 
plasmids/siRNAs using Lipofectamine 2000. Cells were washed with cold-
phosphate buffered saline (PBS) and collected by low speed centrifugation. 
Cells were then lysed in 500 μL lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 10% glycerol, 2 mM EDTA, 1% NP-40, 1 mM phenylmethylsulfonyl 
sulfate (PMSF), protease inhibitor cocktails (Sigma) and 1 mM DTT), 
homogenized and incubated on ice for 30 min. Lysates were cleared by 
centrifugation at 13,000 rpm for 20 min at 4ºC and proteins were resolved by 
10-12% SDS-PAGE. For RanBP2 detection proteins were resolved by 4-20% 
gradient SDS-PAGE gels (Biorad). In any case, proteins were transferred onto 
Immobilon-FL PVDF membranes (Millipore) by using a wet-transfer system 
(Biorad) at 150 mA and 4ºC during 2 hours. Immunoblotting was performed 
according to Odyssey LI-COR Biosciences instructions. The following primary 
antibodies were used for immunoblotting analysis: mouse monoclonal anti-Flag 
(M2, Sigma), mouse anti-tubulin (T9026, Sigma), rabbit anti-Polλ (A301-640A, 
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Bethyl) and mouse monoclonal anti-RanBP2 antibody (sc-74518, Santa Cruz). 
After washes with TBS-0.1% Tween20, membranes were incubated with the 
corresponding IRDye 800CW/680RD secondary antibodies (LI-COR 
Biosciences; 1/15,000) supplemented with 0.1% Tween20, washed again and 
were allowed to dry to be then analysed in Odyssey infrared imaging system 
with the ImageStudio Odyssey CLx Software (LI-COR). Quantification of relative 
band intensities was carried out using ImageJ software. For 
immunoprecipitations, 293T cells were cultured as before and co-transfected 
with both p3xFlag-POLL-Myc-CMV and HA-RanBP2 plasmids using 
Lipofectamine 2000 according to the manufacturer’s instructions. After 24 h, 
cells were harvested, lysed in 500 μL lysis buffer and incubated on ice for 30 
min. Lysates were cleared by centrifugation as indicated before and input 
samples saved for subsequent analysis. Remaining supernatants were 
incubated with mouse monoclonal anti-HA antibody (Sigma) overnight at 4ºC. 
Immuno-complexes were then incubated with Protein G-coupled Dynabeads 
(Life Technologies) for 4 h with end-to-end mixing at 4°C. Beads were washed 
twice in lysis buffer and bound immuno-complexes were released by boiling 
samples in Laemmli buffer. Proteins were resolved by 4-20% gradient SDS-
PAGE gels (Biorad) and processed for western blotting as indicated before. 
Input lysate (10%) was loaded alongside unless otherwise stated. For His-
tagged SUMO pulldown assays, 3x105 human U2OS HIS-SUMO1- and -SUMO2 
expressing cells were seeded in P60 dishes, cultured for 24 h and then 
transfected with 3xFlag-POLL-Myc-CMV expression vectors as indicated 
before. After 48 h, cells were washed and collected by centrifugation in ice-cold 
PBS and stored until processing. For pulldown assays to detect endogenous 
SUMOylation of Polλ, cells were seeded in P100 dishes and 2-4x106 cells were 
processed. In any case, cell extracts were then prepared under denaturing 
conditions by incubation in 500 μL of urea lysis buffer (8 M urea, 0.1 M Tris/HCl 
pH 6.8, 0.2% Triton-X100) during 30 min with rotation at room temperature. 
Lysates were cleared by centrifugation at 13,000 rpm for 10 min at room 
temperature. Input samples were saved and His-tagged SUMO-conjugated 
proteins were pulled down from cell extracts by using Ni-NTA agarose beads 
(Life Technologies). Pulled down proteins were washed 3 times in lysis buffer 
supplemented with 10 mM imidazole and finally eluted in lysis buffer 
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supplemented with 250 mM imidazole and Laemmli buffer. Eluted SUMO-
conjugated proteins were boiled and loaded onto 10% SDS-PAGE. Input lysate 
(5%) was loaded alongside unless otherwise stated. When indicated, cells were 
treated with different drugs and DNA damaging agents: etoposide, hydrogen 
peroxide, MMS and HU (Sigma). After treatment, cells were rinsed using PBS 
and processed as indicated before. 
 
Immunofluorescence 
For standard immunofluorescence studies approximately 2×104 U2OS cells 
were seeded onto sterile glass coverslips in each well of a four-well dish, 
cultured for 24 hours and transfected with Flag-POLL constructs as described 
above. For immunofluorescence studies involving siRNA-mediated silencing of 
endogenous Polλ or RanBP2, 2.5×104, U2OS cells were seeded onto sterile 
glass coverslips in each well of a four-well dish and cultured for 24 hours. 
Silencing of endogenous POLL or RANBP2 was performed as described above. 
After 72 h, cells were fixed by treatment with 4% formaldehyde in PBS at room 
temperature for 10 min, and then permeabilized by treatment with 0.2% Triton 
X-100 in PBS. Cells were incubated with PBS-1% BSA for 30 min to block non-
specific antigens, and then were incubated with mouse monoclonal anti-Flag 
M2 (Sigma; 1/5,000) diluted in PBS-1% BSA. After washes with PBS-0.1% 
Tween20, cells were incubated with Alexa 594 Fluor-conjugated secondary 
antibodies (Jackson; 1/1,000) and washed again as described above. Finally, 
they were counterstained with 4,6 diamidino-2-phenylindole (DAPI 1 μg/ml; 
Sigma) and mounted using Vectashield mounting medium (Vector 
Laboratories). Samples were visualized and pictures taken by using a Leyca 
DM6000B fluorescence microscope with a HCX PL APO 63x/NA 1.40 oil 
immersion objective. For proximity ligation assays (PLA) human U2OS cells 
were grown on sterile glass coverslips and co-transfected with both HA-RanBP2 
and Flag-Polλ as described before. For PLA assays to analyze and measure 
endogenous Polλ and γH2AX proximity, transfection step was omitted. After 48 
hours, cells were fixed and permeabilized as described above. PLA assays 
were performed using the Duolink PLA kit (Sigma) according to manufacturer’s 
instructions with following antibodies: rabbit anti-Polλ (A301-640A Bethyl; 
1/1,000), mouse monoclonal anti-RanBP2 antibody (sc-74518, Santa Cruz; 
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1/1,000) and mouse monoclonal anti-γH2AX (clone JBW301, Millipore; 
1/1,000). For PLA assays measuring transfected Flag-Polλ (either si-RNA 
resistant WT or 7KR mutant) and γH2AX proximity, positively transfected cells 
were identified by performing post-PLA staining by using Alexa A488 fluor-
conjugated anti-rabbit secondary antibodies (Jackson; 1/1,000). After final wash 
step, cells were counterstained with DAPI and mounted as described above. 
Confocal analysis was performed with a Leica confocal microscope TCS SP5, 
using a HCX PL APO lambda blue 63x 1.4 objective with zoom 3. Image stacks 
were captured keeping a step size of 0.5 microns and sequential scanning was 
defined for each channel using 543 nm, 488 nm and 405 nm laser lines, 
respectively. 
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TABLE AND FIGURE LEGENDS 
 
Figure 1. SUMOylation of human Polλ. (A) In vitro SUMOylation reactions 
with indicated purified human proteins were carried out as described in 
Materials and methods. Proteins were resolved by SDS-PAGE and 
immunoblotted (IB) with anti-Polλ antibody. Unmodified and SUMO-conjugated 
Polλ are indicated. (B) U2OS cells stably expressing either His-SUMO1 or His-
SUMO2 were transiently transfected with empty or Flag-Polλ encoding vectors. 
His-SUMO-conjugates were pulled down on Ni-NTA beads (Ni-PD) under 
denaturing conditions (Materials and methods) and immunoblotted (IB) with 
anti-Flag antibody. Expression of Flag-Polλ was monitored by immunoblotting of 
cell lysates (input). An U2OS cell line without genomic integration of tagged 
SUMO proteins was assayed in parallel as a control of specificity. Unmodified 
and SUMO-conjugated Flag-Polλ are indicated. M denotes the molecular mass 
markers in kDa (C) Human Polλ domain organization. Main conserved PolX 
domains [42] and the localization of putativ  SUMO acceptor lysines in the N-
terminal region are indicated. (D) Identification of SUMO conjugation sites using 
peptide arrays. Peptides are numbered sequentially from the starting Met (M) 
codon. Each spot in the array represents Polλ derived peptides formed by the 
indicated consecutive residues with 10-amino acid overlap with the previous 
peptide. Polarity of peptides with respect to membrane attachment is indicated 
with an arrow. K27 is indicated in green and neighbour lysines are marked in 
bold. The peptide array was subjected to an in vitro SUMOylation assay as 
described in Materials and methods and then immunoblotted with anti-SUMO1 
antibody (right panel). Positive SUMO-conjugated peptides generated dark 
spots whereas non-conjugated peptides leave blank spots. Left panel 
represents Ponceau staining of the array. (E, F) U2OS cell lines with integrated 
His-SUMO1 (E) or His-SUMO2 (F) were transiently transfected either with wild-
type Flag-Polλ or Flag-Polλ K27R, 7KR and 6KR mutants. His-SUMO-
conjugates were pulled down on Ni-NTA beads (Ni-PD) as in (B) and 
immunoblotted (IB) with anti-Flag antibody. Expression of Flag-Polλ variants 
was monitored by immunoblotting of cell lysates (input). Unmodified and 
SUMO-conjugated Flag-Polλ are indicated. 
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Figure 2. Subcellular localization of Polλ is controlled by SUMOylation. (A) 
Human U2OS cells were transiently transfected with different Flag-Polλ 
versions (either WT or K23R, K27R, K23/27R, 7KR or 6KR mutants) and 
subcellular localization of Polλ was examined by immunofluorescence using 
anti-Flag antibody (red). Nuclei were stained with DAPI (blue). Merge of both 
Flag and DAPI signals is also shown. Polλ expressing cells were blindly scored 
for their Polλ subcellular localization, and classified in one of the following three 
categories: mainly nuclear, equally distributed between nucleus and 
cytoplasmic (Nuc ≈ Cyto) or mainly cytoplasmic. Representative images for 
each condition are shown in the left panel. The experiment was performed three 
independent times, with more than 100 independent cells counted each time. 
The mean percent localization of each condition is plotted, and error bars 
represent the SD of each data set. Analysis of variance (Anova) was used to 
test for significance in differences in subcellular localization of Polλ variants (**, 
p<0.01; *** p<0.001). (B) Human His-SUMO1 U2OS cells were treated with 
specific POLL siRNAs, as previously described [15], and then transiently co-
transfected with either Flag-empty vector or siRNA-resistant versions of Flag-
Polλ (WT and 7KR). Resistance to siRNA-mediated silencing was confirmed by 
immunoblotting (IB) with anti-Polλ antibody (green). Immunoblotting with anti-
tubulin (red) was used as a loading control. (C) Human His-SUMO1 U2OS cells 
treated as in (B) were subjected or not to etoposide treatment (20 µM, 30 min) 
and processed for PLA using anti-Polλ and anti-phosphoH2AX (γH2AX) 
antibodies. PLA foci (red) were counted in transfected cells. Plots display the 
median values (black bar) for nuclear γH2AX/Polλ PLA foci in each 
experimental condition (untreated WT, 8.0; untreated 7KR, 5.0; etoposide WT, 
47.5; etoposide 7KR, 18.0) plus interquartile range (25th and 75th percentiles). 
The statistical significance was calculated using GraphPad Prism 5.0; p<0.001 
in one-way Anova analysis of variance test of three independent experiments, 
with >35 individual cells analyzed for each condition in each independent repeat 
(total number of cells scored: WT untreated, 147; 7KR untreated, 122; WT 
etoposide, 127; 7KR etoposide, 108). (D) Representative images of one 
experiment described in (C). γH2AX/Polλ PLA foci are shown in red. Flag-Polλ 
transfected cells (in green) were identified by performing post-PLA staining by 
using secondary A488-conjugated anti-rabbit antibodies. Nuclei are stained with 
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DAPI (blue). 
 
Figure 3. Physical and functional interaction of RanBP2 and Polλ at the 
nuclear envelope. (A) Human U2OS cells were transiently co-transfected with 
a plasmid encoding for HA-RanBP2 together with either Flag-POLL WT or Flag-
empty (ev) vectors. Proximity ligation assays (PLA) were performed by using 
mouse monoclonal anti-RanBP2 and rabbit anti-Polλ antibodies. Subcellular 
localization of PLA foci (red) was detected by using confocal laser scanning 
microscopy and nuclei were stained with DAPI (blue). X/Z views are shown in 
upper and middle panels, with merged images included in the right panels; an 
X/Y view is also shown in bottom panels, only with Flag-Polλ WT transfected 
cells. Scale bars, 10 μm. (B) Human 293T cells were transiently transfected as 
in (A) and HA-RanBP2 was immunoprecipitated 24 h later with anti-HA 
antibody. Recovered immunocomplexes were analyzed in 4-20% SDS-PAGE 
and immunoblotting with anti-HA, anti-Flag and anti-tubulin antibodies. (C) 
Human His-SUMO1 U2OS cells were treat d either with control (luciferase) or 
RanBP2 siRNAs and 24 h later transiently transfected with Flag-POLL WT 
vector. SUMO-Polλ conjugates were pulled down on Ni-NTA beads under 
denaturing conditions at indicated times post-transfection and immunoblotted 
with anti-Flag antibody (upper panel). Expression of RanBP2, Flag-Polλ and 
tubulin was monitored by immunoblotting of cell lysates with the corresponding 
antibodies (input). (D) Human His-SUMO1 U2OS cells were treated as in (C) 
and pulled down on Ni-NTA beads under denaturing conditions performed 48 h 
after vector transfection. Quantification represents percentage of SUMOylated 
Polλ in cells (mean value ± standard deviation, SD) for each condition analyzed 
in three independent experiments. Statistical significance was determined by 
using an unpaired t-test. (E) Human His-SUMO1 U2OS cells were treated as in 
(C) and subcellular localization of Flag-Polλ was examined by 
immunofluorescence using anti-Flag antibody (red). Nuclei were stained with 
DAPI (blue). Representative images of one experiment are shown. Scale bars, 
25 μm. Quantification represents percentage of nuclear Polλ in cells (mean 
value ± standard deviation, SD) for each condition analyzed in three 
independent experiments, with more than 50 individual cells analyzed for each 
condition in each independent repeat. Statistical significance was determined 
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by using an unpaired t-test. 
 
Figure 4. Increased SUMOylation of Polλ in response to DNA damage. (A) 
His-SUMO1 and -SUMO2 U2OS cells were grown in p100 dishes until 80% 
confluence and then harvested. His-SUMO-conjugates were pulled down on Ni-
NTA beads (Ni-PD) under denaturing conditions and endogenous SUMO-Polλ 
was detected by immunoblotting (IB) using anti-Polλ antibody. Expression of 
Polλ and tubulin was monitored by immunoblotting cell lysates (input) with the 
corresponding antibodies. (B) His-SUMO2 U2OS cells were grown as described 
in (A) and either mock-treated or treated with etoposide (20 µM, 30 min), 
hydrogen peroxide (750 µM, 1 h),  MMS (0.03%, 30 min), HU (2 mM, 2h) before 
harvesting. His-SUMO-conjugates were pulled down on Ni-NTA beads (Ni-PD) 
and endogenous SUMO-Polλ was detected as described in (A). Expression of 
Polλ and tubulin was monitored by immunoblotting of cell lysates (input) with the 
corresponding antibodies. DNA damage induction was confirmed by 
immunoblotting of cell lysates (input) with anti-phosphorylated H2AX (γH2AX) 
antibody. (C) His-SUMO2 U2OS cells were grown as in (A) and treated with 
increasing doses of either MMS (0.01%, 0.02% and 0.03%, 30 min) or HU (3 
and 5 mM, 2h). His-SUMO-conjugates were detected as described above. 
Expression of Polλ and tubulin was monitored and replicative stress induction 
was confirmed with anti-phosphorylated (S4/S8) RPA antibody. (D) His-SUMO2 
U2OS were synchronized in G1 by using thymidine block, as previously 
described [56]. Thymidine block was released from G1-enriched cultures and 
His-SUMO conjugates were pulled down at different times as indicated in (A). 
Recovering times were selected according to [56]. Cell progression at different 
stages of the cell cycle was monitored by immunoblotting with anti-cyclin A and 
E antibodies, and expression of Polλ and tubulin was monitored as described 
before.
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Supplemental Figure 1. SUMOylation of human Polλ (A) In vitro SUMOylation 
assay. Reactions were carried out with purified human Polλ and the indicated 
purified murine SUMOylation proteins in standard SUMO reaction buffer (see 
Materials and methods). When indicated, ATP was added to trigger catalytic 
reactions leading to SUMO conjugation. Proteins were resolved by SDS-PAGE 
and Polλ was detected by immunoblotting (IB) with anti-Polλ antibodies. In vitro 
reactions produced ATP-dependent Polλ-SUMO conjugates with slower 
electrophoretic migration compared with unmodified Polλ. Both unmodified and 
SUMO-conjugated Polλ are indicated. (B) In vitro SUMOylation assays were 
performed as in (A), including a GST-SUMO1 fusion protein to confirm Polλ 
SUMOylation. Proteins were resolved by SDS-PAGE and Polλ was detected by 
immunoblotting (IB) with anti-Polλ antibodies. The corresponding Polλ-SUMO 
conjugates with slower electrophoretic migration compared with unmodified 
Polλ obtained are indicated. GST-SUMO1-Polλ species are in agreement with 
additional 25 kDa size corresponding to GST protein. (C) In vivo SUMOylation 
assays. Human 293T cells were transiently transfected with plasmids encoding 
for Flag-Polλ, His-SUMO1 and either Ubc9 or dominant negative mutant Ubc9-
C93S. SUMO conjugates were purified from cell lysates 48 h later by Ni-NTA 
pulldown (PD) assays under denaturing conditions. Polλ SUMOylation was 
detected by immunoblotting (IB) using anti-Flag antibodies. SUMO-Polλ 
conjugates are observed as slower migrating species compared with 
unmodified Flag-Polλ. Both unmodified and SUMO-conjugated Polλ are 
indicated. 
 
Supplemental Figure 2. Identification of SUMO sites in human Polλ. (A) 
Sequence alignment of Polλ N-terminal regions from different species. Lysine 
27 (K27) is embedded into the non-consensus site for SUMOylation (AKIP in 
human sequence), and is marked in green over black background. An acidic 
patch located downstream from K27 is marked in red. The beginning of the 
BRCT domain (amino acid residues 35-125) and a predicted nuclear 
localization signal (amino acid residues 11-17) are also indicated [55]. (B) 
Identification of Polλ SUMO conjugation sites in silico. Analysis of human Polλ 
amino acid sequence with SUMOplotTM software identifies lysine 27 as the 
residue with the greatest potential to be modified by SUMO conjugation. Only 
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lysine residues with highest score are shown. (C) Identification of SUMO2 
conjugation sites in human Polλ by proteome-wide assays [29]. 
 
Supplemental Figure 3. Effect of leptomycin B in Polλ 7KR subcellular 
localization. Human U2OS cells were transiently transfected with Flag-tagged 
Polλ 7KR mutant. After 24 h, transfected cells left untreated (-LMB) or treated 
with 10 ng/µl LMB for 6 h (+LMB), and cellular localization of Flag-Polλ was 
examined by immunofluorescence staining using anti-Flag antibody (red). 
Nuclei were stained with DAPI (blue). Merge of both Flag and DAPI signals is 
also shown. Scale bars (bottom-right corner), 10 μm. 
 
Supplemental Figure 4. Subcellular localization of constitutive SUMO-Polλ 
versions (A) (Upper) Scheme of constitutive SUMO-Polλ 7KR constructs 
generated by the in-frame fusion of SUMO1 or SUMO2 human cDNA at the N-
terminus of Polλ cDNA in the 3xFlag-POLL7KR-myc mammalian expression 
vector to generate S1-fus and S2-fus SUMO-Polλ7KR fusion proteins, 
respectively. Localization of the C-terminal di-glycine (GG) motif critical for 
SUMO conjugation is marked with an asterisk. GG motif was mutated to di-
alanine (AA) in the mutants S1-fus and S2-fus to impede SENP proteases 
action that cause breakage of SUMO-Polλ conjugation (bottom panel). Human 
Polλ conserved PolX domains are: BRCT, BRCA1 C-terminal domain; SP-rich, 
Ser-Pro rich domain; catalytic, Polß-core domain [56]. The localization of lysine 
residues in the N-terminal region of Polλ is indicated. (Bottom) Human U2OS 
cells were transiently transfected with vectors encoding the indicated Flag-
tagged Polλ versions and expression of corresponding fusion proteins was 
analyzed by immunoblotting of whole cell extracts with anti-Polλ antibody 
(green). Tubulin (red) was used as a loading control. In-frame SUMO-Polλ 
fusions S1-fus (AA) and S2-fus (AA) generated proteins with increased 
molecular weight over Flag-tagged Polλ according to SUMO moiety (around 20 
kDa). S1-fus (GG) and S2-fus (GG) proteins were degraded by SENPs leading 
to an overexpressed product with the same size as endogenous Polλ, also 
indicated. (B) Subcellular localization of Flag-tagged Polλ wild-type and 7KR 
mutants, including constitutive SUMO-Polλ fusion proteins S1-fus (AA) and S2-
fus (AA), using confocal laser scanning microscopy. U2OS cells were 
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transiently transfected with the indicated plasmids and cellular localization of 
Flag-Polλ was examined by immunofluorescence using both anti-Flag (red) and 
Polλ (green) antibodies. Nuclei were stained with DAPI (blue). Representative 
images for each condition are shown. Scale bars, 7.5 μm. 
 
Supplemental Figure 5. Proximity ligation assays to measure Polλ-mediated 
DSB repair. Human U2OS cells were mock treated or exposed to the indicated 
doses of etoposide for 30 minutes to induce DNA DSBs. Cells were then 
processed for proximity ligation assays (PLA) using rabbit anti-Polλ and mouse 
anti-phosphorylated H2AX (γH2AX) antibodies. Cells were blindly scored for 
PLA foci (in red) and nuclei were stained with DAPI (blue). Plot displays the 
mean values (± standard deviation, SD) of three independent experiments, with 
more than 50 individual cells analyzed for each condition in each independent 
repeat. Total number of independent cells scored: untreated, 175; 10 µM, 346; 
20 µM, 284; 50 µM, 289; 100 µM, 303. The statistical significance was 
calculated using GraphPad Prism 5.0; p<0.001 in one-way Anova analysis of 
variance test. Representative images of one experiment are shown in the upper 
panel. Scale bar represents 10 μm. 
 
Supplemental Figure 6. Subcellular localization of siRNA-resistant WT or 7KR 
mutant Polλ in PLA assays after etoposide treatment. Human U2OS cells were 
subjected to siRNA-mediated silencing of endogenous POLL expression, and 
subsequently transfected with plasmids encoding for siRNA resistant WT or 
7KR mutant Polλ. Cells were then either mock-treated or treated with etoposide 
(20 µM, 30 min) and processed for PLA as described in Materials and methods. 
Positively transfected cells were identified by performing post-PLA staining by 
using Alexa A488 fluor-conjugated anti-rabbit secondary antibodies, and are 
shown in green. Nuclei were stained with DAPI (blue). Representative images 
of experiments quantified in Figure 2C are shown: top panels show subcellular 
localization of siRNA-resistant WT Polλ in either untreated (A) or etoposide-
treated (B) cells; medium and bottom panels show images of siRNA-resistant 
Polλ 7KR mutant in either untreated (C,E) or etoposide-treated (D,F) cells. 
Scale bars in panels A-D, 10 μm. Scale bars in panels E-F, 25 μm 
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Supplemental Figure 7. RanBP2-Polλ co-localization at the nuclear pore 
complex. Human U2OS cells were transiently transfected with a plasmid 
encoding for HA-tagged RanBP2 together with either Flag-tagged Polλ WT or 
Flag-empty vector (ev). Proximity ligation assays (PLA) were performed by 
using mouse monoclonal anti-RanBP2 and rabbit anti-Polλ antibodies and 
subcellular localization of PLA foci was performed by using confocal laser 
scanning microscopy. RanBP2-Polλ proximity is indicated with red PLA foci. 
Nuclei were stained with DAPI (blue). Complete series of X/Z views are shown, 
with merged images also included in the right. Scale bars, 10 μm. 
 
Supplemental Figure 8. Increased SUMOylation of Polλ in response to HU. 
His-SUMO1 and -SUMO2 U2OS cells were grown in p100 dishes until 80% 
confluence, either mock-treated or treated with increasing doses of HU (1 mM, 
2 mM and 3 mM) for 2 h, and the harvested. His-SUMO-conjugates were pulled 
down on Ni-NTA beads (Ni-PD) under denaturing conditions and endogenous 
SUMO-Polλ was detected by immunoblotting (IB) using anti-Polλ antibody. 
Expression of Polλ and tubulin was monitored by immunoblotting cell lysates 
(input) with the corresponding antibodies. 
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Research Highlights 
 
Human Polλ is modified by SUMOylation, both in vitro and in vivo 
SUMOylation mainly targets Polλ lysine 27 (K27) residue 
SUMOylation promotes nuclear localization of Polλ 
Polλ SUMOylation is dependent on the nuclear pore complex-associated E3 
ligase RanBP2 
Polλ SUMOylation increases by DNA damage, and allows Polλ recruitment to 
repair DNA double strand breaks 
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